Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Lundbeck
  6. Summary
    LUN   DK0061804697

LUNDBECK

(LUN)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-07-01 am EDT
35.60 DKK   +4.52%
06/27TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
06/27CORRECTION ( : Markets-Morning UPDATE1:)
AQ
06/27H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
37.7(c) 35.8(c) 34.6(c) 34.06(c) 35.6(c) Last
1 592 992 800 082 181 071 296 040 610 293 Volume
+11.87% -5.04% -3.35% -1.56% +4.52% Change
More quotes
Estimated financial data (e)
Sales 2022 17 258 M 2 413 M 2 413 M
Net income 2022 1 521 M 213 M 213 M
Net Debt 2022 1 973 M 276 M 276 M
P/E ratio 2022 -
Yield 2022 -
Sales 2023 18 798 M 2 629 M 2 629 M
Net income 2023 2 558 M 358 M 358 M
Net cash position 2023 1 207 M 169 M 169 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 35 750 M 4 999 M 4 999 M
EV / Sales 2022 2,19x
EV / Sales 2023 1,84x
Nbr of Employees 5 353
Free-Float 30,7%
More Financials
Company
H. Lundbeck A/S specializes in the development, production and marketing of medicines for the treatment of psychiatric and neurological disorders (depression, schizophrenia, Lennox-Gastaut syndrome, Parkinson's disease, Huntington's disease, epilepsy, sleep disorders, etc.). 
Read more
Sector
Pharmaceuticals
Calendar
08/17Earnings Release
More about the company
Ratings of Lundbeck
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about LUNDBECK
06/27TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
06/27CORRECTION ( : Markets-Morning UPDATE1:)
AQ
06/27H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agi..
CI
06/26Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation ..
AQ
06/20Otsuka's European Unit Gets Clearance to Market Schizophrenia Drug
MT
06/17European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectab..
CI
06/16Results from the DELIVER study with Vyepti® has been published in a top-ranking medical..
AQ
06/16H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti
CI
06/14H. LUNDBECK A/S(CPSE : HLUN A) added to OMX Nordic All-Share Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to OMX Nordic All-Share Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
CI
06/09H. LUNDBECK A/S(CPSE : LUN) dropped from OMX Nordic All-Share Index
CI
06/08Lundbeck Extraordinary General Meeting on June 8, 2022 at the company's registered offi..
AQ
06/08TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
More news
News in other languages on LUNDBECK
06/27POINT SUR LES FORTES VARIATIONS DU J : Prosus s'éloigne de Tencent
06/27H. Lundbeck A/S et Otsuka Pharmaceutical annoncent des résultats positifs montrant une ..
06/17L'Agence européenne des médicaments commence l'examen de l'injectable à action prolongé..
06/16H. Lundbeck A/S annonce les résultats de l'étude Deliver avec Vyepti
06/15L'agenda di oggi
More news
Analyst Recommendations on LUNDBECK
More recommendations
Chart LUNDBECK
Duration : Period :
Lundbeck Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUNDBECK
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 35,60 DKK
Average target price 167,00 DKK
Spread / Average Target 369%
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders Götzsche Chief Financial Officer & Executive Vice President
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LUNDBECK-78.92%4 999
JOHNSON & JOHNSON3.76%472 389
PFIZER, INC.-11.21%293 506
ELI LILLY AND COMPANY17.38%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782